Pharmacogenetics (PGx) of CYP2D6 is gaining more importance in routine clinical settings. CYP2D6 is susceptible to inhibition. Thus, including phenoconversion effects (PC) in result interpretation may maximize precision benefits of PGx. However, studies including the functional enzyme status (PC-informed PGx) are lacking.
No takes yet. Share an insight, caveat, or question.
Scherf‐Clavel et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: